Jefferies Upgrades Vivus (VVUS) to Hold
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Price: $14.60 +0.69%
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 15 | New: 13
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 15 | New: 13
Trade VVUS Now!
Jefferies upgraded Vivus (NASDAQ: VVUS) from Underperform to Hold with a price target of $31.00 (from $9.00).
The firm comments, "The FDA approved Qsymia (formerly Qnexa), which we see as a major win for VVUS. The label and REMS contains surprises, which include physician registration and a more complex titration regimen. Although some questions remain on commercial challenges, we are positive on the initial sales trajectory and have added a partnership to our model and revised our estimates to account for increased duration."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $26.46 yesterday, with a 52 week range of $6.13-$29.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "The FDA approved Qsymia (formerly Qnexa), which we see as a major win for VVUS. The label and REMS contains surprises, which include physician registration and a more complex titration regimen. Although some questions remain on commercial challenges, we are positive on the initial sales trajectory and have added a partnership to our model and revised our estimates to account for increased duration."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $26.46 yesterday, with a 52 week range of $6.13-$29.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- Oracle Investment Research Upgrades Procter & Gamble (PG) to Hold
- Vivus (VVUS) Sees Upside on Icahn Connection
Create E-mail Alert Related Categories
UpgradesRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
